NCT03402399

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 222 (estimated)
• Sponsor: Assaf-Harofeh Medical Center · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.

Detailed description

Main inclusion criteria: 1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification 2. Age ≥ 18 years 3. Concurrent participation in clinical trials will be allowed. Efficacy assessments will be evaluated by: HMR mutations rate, specific HMR mutations, disease duration, presence of splenomegaly, cytogenetic risk, DIPPS, IPSS, ET survival score and PV survival score. The primary efficacy parameter to be assessed will be HMR mutation rate.

Conditions

• Myelofibrosis, Primary
• Myelofibrosis, Post PV
• Myelofibrosis, Post ET

Interventions

Type	Name	Description
OTHER	Molecular analysis	Blood test

Timeline

• Start date: 2017-12-10
• Primary completion: 2019-12-09
• Completion: 2020-12-09
• First posted: 2018-01-18
• Last updated: 2019-07-05

Locations

1 site across 1 country: Israel